Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab in Relapsed or Refractory Multiple Myeloma
NCT04634552Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2021
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of talquetamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Feb 2021; status: recruiting.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04634552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634552.